Articles from Celerion

Celerion, a global leader in early clinical research and bioanalytical services, today announced the expansion of its bioanalytical laboratory in Zurich, Switzerland. The investment strengthens Celerion’s ability to support increasing global demand for bioanalytical services, providing clients with enhanced capacity, rapid study execution, and access to specialized scientific expertise across complex drug development programs.

Celerion, a global leader in early-stage clinical research, announced the appointment of Dr. Steven Evans as Senior Cardiologist. In his new role, Dr. Evans will strengthen the company’s commitment to participant safety and data integrity by providing expert cardiovascular oversight.

Celerion, a leader in early clinical research, proudly announces its achievement of a full AAHRPP (Association for the Accreditation of Human Research Protection Programs) reaccreditation for five years by the Council on Accreditation of AAHRPP. Celerion is the only CRO headquartered in the USA to hold this distinguished accreditation. This prestigious recognition underscores Celerion's unwavering dedication to maintaining the highest ethical standards, safeguarding participant welfare, and fostering excellence in clinical research.

Celerion, a global leader in early clinical research and bioanalytical services, announced the launch of the latest version of Labnotes, its cutting-edge bioanalytical electronic laboratory notebook software elevating data handling and analysis capabilities for sponsors.

Celerion, a global leader in early clinical research, proudly announces a new agreement to relocate its U.K. Phase 1 clinical research operations to iREACH Health. This state-of-the-art clinical research center, led by Queen’s University Belfast, in partnership with the Belfast Health and Social Care Trust, is set to become a cornerstone of Northern Ireland’s life sciences innovation ecosystem upon its early 2027 completion.

Celerion, a global leader in early clinical research, is proud to announce its commitment to the Science Based Targets Initiative (SBTi), reinforcing its dedication to sustainable corporate climate action. By aligning with the SBTi and its ambitious goals, Celerion aims to set both Near Term and Net Zero company-wide emission reduction targets in line with science-based standards.

Celerion, a leading clinical research organization specializing in early clinical research and bioanalytical services, announces the launch of on-site services for rapid sterility testing (validated alternative method to USP <71>) and dose formulation analysis.

Celerion, a leading clinical research organization, is pleased to announce it has received a CRO Leadership Award for the ninth time by global biopharmaceutical executives in Life Science Leader’s annual CRO Leadership Awards for 2024.

Celerion, a leading clinical research organization, specializing in early clinical research and bioanalytical services, today announced the appointment of Jo Goodman as vice president of bioanalytical services in its Lincoln, Nebraska, laboratory.

Celerion, a leading clinical research organization, proudly announces its recent achievement of obtaining the Clinical Laboratory Improvement Amendments (CLIA) certification for its state-of-the-art bioanalytical laboratory located in Lincoln, Nebraska. This significant milestone marks a pivotal step in Celerion’s commitment to advancing healthcare by integrating high-complexity testing and diagnostic services into its comprehensive suite of bioanalytical solutions.

Celerion, a leading clinical research organization, has been recognized for the eighth consecutive year as the winner of a CRO Leadership Award by global biopharmaceutical executives in Clinical Leader and Life Science Leader’s annual CRO Leadership Awards for 2023.

Celerion, a clinical research organization (CRO) to the biopharmaceutical industry, announces the expansion of molecular and cellular capabilities to Good Laboratory Practice/Good Clinical Practice (GLP/GCP) standards to support the development of new modality therapies, such as cell and gene therapies. The expanded service offering is available in both of the company’s Lincoln and Zürich bioanalytical laboratories and includes ELISpot analysis, flow cytometry, and qPCR.